Does this study provide enough evidence to reclassify GLP-1 receptor agonists primarily as cardiovascular preventative therapies rather than metabolic or weight-management drugs?
Open Internet by MindsNet
Does this study provide enough evidence to reclassify GLP-1 receptor agonists primarily as cardiovascular preventative therapies rather than metabolic or weight-management drugs?